Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High Glucose Levels Predict Mortality in Pneumonia

By LabMedica International staff writers
Posted on 01 Oct 2012
Nondiabetic patients who have elevated serum glucose levels when they are admitted to the hospital with pneumonia have an increased risk of dying within 90 days.

Acute hyperglycemia associated with community-acquired pneumonia (CAP) can identify at-risk patients who need additional care to reduce their risk for mortality, compared with similar normoglycemic patients.

Scientists from the University Hospital of Saarland (Homburg, Germany) evaluated whether acute dysglycemia could predict a poor outcome in patients with CAP who had not been diagnosed with diabetes. They studied data from 6,891 adults with CAP who were enrolled in a prospective study from 2003 to 2009. The investigators also calculated various comorbidities for one month, three months and six months mortality on the basis of serum glucose levels at hospital admission. The majority of the patients were male, and the mean age was 60 years.

At the time of hospital admission, patients who had glucose levels from 6 to 11 mmol/L (108-198 mg/dL) were considered to have mild acute hyperglycemia and patients who had glucose levels of 14 mmol/L (252 mg/dL) or more were considered to have acute hyperglycemia. In all, 40% of CAP patients presented with hyperglycemia. An elevated glucose level at hospital admission was an independent predictor of one month, three months and six months mortality in CAP patients. In fact, increasing glucose levels corresponded to increasing risk for death from CAP.

Patients with mild to moderate hyperglycemia had a significantly higher hazard ratio (HR) for mortality at 90 days than patients with normal glucose levels at hospital admission. In patients presenting with acute hyperglycemia, HR increased to 6.04. In patients previously diagnosed with diabetes, there was no association between glucose level at admission and mortality. However, there was a nearly two-fold increased risk of dying in the 16% of patients with preexisting diabetes.

Philipp M. Lepper, MD, the senior investigator, said, "Increased serum glucose levels at admission are a risk factor for death among patients with community-acquired pneumonia. The risk for mortality starts to increase when serum glucose levels are slightly increased but remain below the defined threshold for overt diabetes." The study was presented on September 2, 2012, at the European Respiratory Society (ERS) 2012 Annual Congress held in Vienna Austria.

Related Links:

University Hospital of Saarland




Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.